Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch. venez. farmacol. ter ; 16(1): 47-53, 1997.
Artigo em Inglês | CUMED | ID: cum-17234

RESUMO

Two hundred and sevently patients with Acute Lymphoblastic Leukemia in the pediatric age were studied and treated during 1969-1993 with different therapeutical shemes which virtually all included in the protocols of the Latin America Group for the Treatment of Malignant Hemopathics (GLATEM). These patients have been treated in different hospitals of Cuba, and most of them were in first complete remission. Of the total of patients, 8 have been treated before GLATEM protocols; 92 were treated with schemes of the 70s and the remaining ones included in more recent protocols. Patients were included in the study once they finished their treatment, and they were followed during several years with clinical and hematological control. Pronostic group classification was carried out mainly in relation to age and leukocyte count., considerating three group:good, intermediate and Poor. The CNS relapses being of the best course and those of bone marrow of the most unfavorable one. An important number of patients had their therapy stopped a second time. The high nomber of patients, event-free for several years without treatment; show that true cures can be attained in All children (AU)


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
2.
Arch. venez. farmacol. ter ; 15(2): 93-100, 1996.
Artigo em Espanhol | CUMED | ID: cum-17235

RESUMO

Se realiza un estudio de 186 niños diagnósticados de leucemia linfoblástica aguda de 1972 a 1995 y tratados con distintos esquemas terapéuticos, casi todos incluidos en los protocolos del grupo latinoamericano de tratamiento de homeopatías malignas. Los grupos se clasificaron en bueno, intermedio y malo. Se encontró una diferencia significativa en los porcentaje de sobrevida BIM en los protocolos de la década de los 70, mientras en los esquemas tipo BFM se borran las diferencias entre bueno e intermedio, persistiendo una sobrevida menor en el grupo de pronóstico malo. Los factores pronósticos analizados en forma aislada que tuvieron importancia significativa en los porcentajes de sobrevida fueron: la edad, la esplenomegalia y la cifra de leucocitos suuperior a 50x10/1 (AU)


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
3.
Arch. venez. farmacol. ter;15(2): 86-92, 1996.
em Espanhol | CUMED | ID: cum-18610

RESUMO

Las afectaciones neoplásicas han adquido una importancia creciente en la pediatría. Grandes han sido los progresos que han ocurrido en el tratamiento integral del niño con cáncer con espectacular mejoría de los resultados obtenidos. Una de las complicaciones más temibles en el manejo de estos pacientes es la infección y en la Leucemia Linfoblastica Aguda representa la causa principal de morbimortalidad.


Assuntos
Neutropenia , Neoplasias
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...